Lymphatic filariasis
From Wikipedia, the free encyclopedia

Lymphatic filariasis

Synonyms  
elephantiasis tropica, elephantiasis arabum[1]

"Bellevue Venus" Oscar G. Mason's portrait of a woman with elephantiasis.

Classification and external resources

Specialty  infectious disease

ICD-10  B74  
(http://apps.who.int/classifications/icd10/browse/2016/en#/B74)

ICD-9-CM  125.0  (http://www.icd9data.com/getICD9Code.ashx?icd9=125.0)-125.9  
(http://www.icd9data.com/getICD9Code.ashx?icd9=125.9)

eMedicine  derm/888  (http://www.emedicine.com/derm/topic888.htm)
Lymphatic filariasis, also known as elephantiasis,\[^2\] is a human disease caused by parasitic worms known as filarial worms.\[^3\] Most cases of the disease have no symptoms.\[^3\] Some people, however, develop a syndrome called elephantiasis, which is marked by severe swelling in the arms, legs, or genitals.\[^3\][^4] The skin may also become thicker, and pain may occur. The changes to the body can cause social and economic problems for the affected person.\[^3\]

The worms are spread by the bites of infected mosquitoes. Three types of worms are known to cause the disease: *Wuchereria bancrofti*, *Brugia malayi*, and *Brugia timori*, with *Wuchereria bancrofti* being the most common. These worms damage the lymphatic system.\[^3\] The disease is diagnosed by microscopic examination of blood collected during the night. The blood is typically examined as a smear after being stained with Giemsa stain. Testing the blood for antibodies against the disease may also permit diagnosis.\[^5\] Other roundworms from the same family are responsible for river blindness.\[^6\]

Prevention can be achieved by treating entire groups in which the disease exists, known as mass deworming. This is done every year for about six years, in an effort to rid a population of the disease entirely. Medications used include antiparasitics such as albendazole with ivermectin, or albendazole with diethylcarbamazine. The medications do not kill the adult worms but prevent further spread of the disease until the worms die on their own. Efforts to prevent mosquito bites are also recommended, including reducing the number of mosquitoes and promoting the use of bed nets.\[^3\]
Lymphatic filariasis is one of the main neglected tropical diseases and one of the four main worm infections. More than 120 million people are infected with lymphatic filariasis and about 1.4 billion people are at risk of the disease in 73 countries. It is most common in tropical Africa and Asia. The disease results in economic losses of many billions of dollars a year.

## Contents

- 1 Signs and symptoms
- 2 Causes
- 3 Diagnosis
- 4 Prevention
- 5 Treatment
  - 5.1 Antibiotics
- 6 Prognosis
- 7 Epidemiology
- 8 History
- 9 Research directions
- 10 References

### Signs and symptoms

The most spectacular symptom of lymphatic filariasis is elephantiasis, a stage 3 lymphedema with thickening of the skin and underlying tissues. This was the first mosquito-borne disease to be discovered. Elephantiasis results when the parasites lodge in the lymphatic system and cause blockages to the flow of lymph. Infections usually begin in childhood.

The skin condition the disease causes is called "elephantiasis tropica" (also known as "elephantiasis arabum").
Elephantiasis mainly affects the lower extremities; the ears, mucous membranes, and amputation stumps are affected less frequently. However, various species of filarial worms tend to affect different parts of the body: *Wuchereria bancrofti* can affect the arms, breasts, legs, scrotum, and vulva (causing hydrocele formation), while *Brugia timori* rarely affects the genitals. Those who develop the chronic stages of elephantiasis are usually amicrofilaraemic and often have adverse immunological reactions to the microfilariae as well as the adult worms.

The subcutaneous worms present with skin rashes, urticarial papules, and arthritis, as well as hyper- and hypopigmentation macules. *Onchocerca volvulus* manifests itself in the eyes, causing "river blindness" (onchocerciasis), one of the leading causes of blindness in the world.[9] [10]

Serous cavity filariasis presents with symptoms similar to subcutaneous filariasis, in addition to abdominal pain, because these worms are also deep-tissue dwellers.

Elephantiasis leads to marked swelling of the lower half of the body.
Life cycle of *Wuchereria bancrofti*, a parasite that causes lymphatic filariasis

Causes

Elephantiasis occurs in the presence of microscopic, thread-like parasitic worms such as *Wuchereria bancrofti* (the most common\(^3\)), *Brugia malayi*, and *Brugia timori* (also known as *B. timori*), all of which are transmitted by bites from infected mosquitoes.\(^{[11]}\) It is a type of helminth infection. Three types of worm cause the disease and damage the lymphatic system:

The disease itself is a result of a complex interplay between several factors: the worm, the endosymbiotic *Wolbachia* bacteria within the
worm, the host’s immune response, and the numerous opportunistic infections and disorders that arise. The adult worms only live in the human lymphatic system. The parasite infects the lymph nodes and blocks the flow of lymph throughout the body; this results in chronic lymphedema, most often noted in the lower torso (typically in the legs and genitals).

**Diagnosis**

The standard method for diagnosing active infection is by finding the microfilariae via microscopic examination. This may be difficult, as in most parts of the world, microfilariae only circulate in the blood at night. For this reason, the blood has to be collected nocturnally. The blood sample is typically in the form of a thick smear and stained with Giemsa stain. Testing the blood serum for antibodies against the disease may also be used.

**Prevention**

The World Health Organization recommends mass deworming—treating entire groups of people who are at risk with a single annual dose of two medicines, namely albendazole in combination with either ivermectin or diethylcarbamazine citrate. With consistent treatment, since the disease needs a human host, the reduction of microfilariae means the disease will not be transmitted, the adult worms will die out, and the cycle will be broken. In sub-Saharan Africa, albendazole (donated by GlaxoSmithKline) is being used with ivermectin (donated by Merck & Co.) to treat the disease, whereas elsewhere in the world, albendazole is used with diethylcarbamazine. Transmission of the infection can be broken when a single dose of these combined oral medicines is consistently maintained annually for a duration of four to six years. Using a combination of treatments better reduces the
number of microfilariae in blood. Avoiding mosquito bites, such as by using
insecticide-treated mosquito bed nets, also reduces the transmission of
lymphatic filariasis.[16][18]

The Carter Center's International Task Force for Disease Eradication declared
lymphatic filariasis one of six potentially eradicable diseases.[16] According to
medical experts, the worldwide effort to eliminate lymphatic filariasis is on
track to potentially succeed by 2020.[19]

For similar-looking but causally unrelated podoconiosis, international
awareness of the disease will have to increase before elimination is possible.
In 2011, podoconiosis was added to the World Health Organization's
Neglected Tropical Diseases list, which was an important milestone in raising
global awareness of the condition.[20] The efforts of the Global Programme to
Eliminate LF are estimated to have prevented 6.6 million new filariasis cases
from developing in children between 2000 and 2007, and to have stopped the
progression of the disease in another 9.5 million people who had already
contracted it.[21] Dr. Mwele Malecela, who chairs the programme, said: "We
are on track to accomplish our goal of elimination by 2020."[19] In 2010, the
WHO published a detailed progress report on the elimination campaign in
which they assert that of the 81 countries with endemic LF, 53 have
implemented mass drug administration, and 37 have completed five or more
rounds in some areas, though urban areas remain problematic.[22]

## Treatment

Treatments for lymphatic filariasis differ depending on the geographic
location of the endemic area.[17] In sub-Saharan Africa, albendazole is being
used with ivermectin to treat the disease, whereas elsewhere in the world,
albendazole is used with diethylcarbamazine.[17] Geo-targeting treatments is
part of a larger strategy to eventually eliminate lymphatic filariasis by 2020.
[17]
Additionally, surgical treatment may be helpful for issues related to scrotal elephantiasis and hydrocele. However, surgery is generally ineffective at correcting elephantiasis of the limbs. A vaccine is not yet available but in 2013 the University of Illinois was reporting 95% efficacy in testing against *B. malayi* in mice.[23]

Treatment for podoconiosis consists of consistent shoe-wearing (to avoid contact with the irritant soil) and hygiene - daily soaking in water with an antiseptic (such as bleach) added, washing the feet and legs with soap and water, application of ointment, and in some cases, wearing elastic bandages.[24] Antibiotics are used in cases of infection.[25]

**Antibiotics**

The antibiotic doxycycline is effective in treating lymphatic filariasis.[26] Its drawbacks are that it requires a 4 to 6 weeks treatment and should not be used in young children and pregnant women, which prevent its use for mass prophylaxis.[26] The parasites responsible for elephantiasis have a population of endosymbiotic bacteria, *Wolbachia*, that live inside the worm. When the symbiotic bacteria of the adult worms are killed by the antibiotic, they no longer provide chemicals which the nematode larvae need to develop, which either kill the larvae or prevent their normal development. This permanently sterilizes the adult worms, which additionally die within 1 or 2 years instead of after their normal 10 to 14 years lifespan.[27]

**Prognosis**

About 40 million people were disfigured or incapacitated by the disease in 2015.[28] Elephantiasis caused by lymphatic filariasis is one of the most common causes of disability in the world.[17] In endemic communities,
approximately 10 percent of women can be affected with swollen limbs, and 50 percent of men can have mutilating genital disease. In areas endemic for podoconiosis, prevalence can be 5% or higher.

**Epidemiology**

A 2012 report noted that lymphatic filariasis affected 120 million people and one billion people at risk for infection. It is considered endemic in tropical and subtropical regions of Africa, Asia, Central and South America, and Pacific Island nations.

In communities where lymphatic filariasis is endemic, as many as 10% of women can be afflicted with swollen limbs, and 50% of men can suffer from mutilating genital symptoms.

Filariasis is considered endemic in 73 countries; 37 of these are in Africa.

- In the Americas, it is present in Brazil, Costa Rica, the Dominican Republic, Guyana, Haiti, Suriname, and Trinidad and Tobago.
- In Asia, it is present in
  - Bangladesh,
  - Cambodia,
  - India,
  - Indonesia,
  - Laos,
  - Malaysia,
  - Maldives,
the Philippines,
- Sri Lanka,
- Thailand,
- Timor-Leste, and
- Vietnam.

- In the Middle East, it is present only in Yemen.
- In the Pacific region, it is endemic in American Samoa, the Cook Islands, Fiji, French Polynesia, Micronesia, Niue, Papua New Guinea, Samoa, Tonga, Tuvalu, and Vanuatu.

In many of these countries, considerable progress has been made towards elimination of filariasis. Elimination of the disease may have been achieved in several countries, but awaits official confirmation by the WHO.

History

Lymphatic filariasis is thought to have affected humans for about 4000 years.\[32\] Artifacts from ancient Egypt (2000 BC) and the Nok civilization in West Africa (500 BC) show possible elephantiasis symptoms. The first clear reference to the disease occurs in ancient Greek literature, wherein scholars differentiated the often similar symptoms of lymphatic filariasis from those of leprosy.

The first documentation of symptoms occurred in the 16th century, when Jan Huyghen van Linschoten wrote about the disease during the exploration of Goa. Similar symptoms were reported by subsequent explorers in areas of Asia and Africa, though an understanding of the disease did not begin to develop until centuries later.

In 1866, Timothy Lewis, building on the work of Jean Nicolas Demarquay and Otto Henry Wucherer, made the connection between microfilariae and elephantiasis, establishing the course of research that would ultimately explain the disease. In 1876, Joseph Bancroft discovered the adult form of the worm. In 1877, the lifecycle involving an arthropod vector was theorized by Patrick Manson, who proceeded to demonstrate the presence of the worms in
mosquitoes. Manson incorrectly hypothesized that the disease was transmitted through skin contact with water in which the mosquitoes had laid eggs. In 1900, George Carmichael Low determined the actual transmission method by discovering the presence of the worm in the proboscis of the mosquito vector. [32]

“Many people in Malabar, Nayars as well as Brahmans and their wives — in fact about a quarter or a fifth of the total population, including the people of the lowest castes — have very large legs, swollen to a great size; and they die of this, and it is an ugly thing to see. They say that this is due to the water through which they go, because the country is marshy. This is called *pericaes* in the native language, and all the swelling is the same from the knees downward, and they have no pain, nor do they take any notice of this infirmity.


Research directions

Researchers at the University of Illinois at Chicago (UIC) have developed a novel vaccine for the prevention of lymphatic filariasis. This vaccine has been shown to elicit strong, protective immune responses in mouse models of lymphatic filariasis infection. The immune response elicited by this vaccine has been demonstrated to be protective against both *W. bancrofti* and *B. malayi* infection in the mouse model and may prove useful in the human. [34]

On September 20, 2007, geneticists published the first draft of the complete genome (genetic content) of *Brugia malayi*, one of the roundworms which causes lymphatic filariasis. [35] This project had been started in 1994 and by 2000, 80% of the genome had been determined. Determining the content of the genes might lead to the development of new drugs and vaccines. [36]
References


36. Williams, SA; Lizotte-Waniewski, MR; Foster, J; Guiliano, D; Daub, J; Scott, AL; Slatko, B; Blaxter, ML (10 April 2000). "The filarial genome project: analysis of the nuclear, mitochondrial and endosymbiont genomes of Brugia malayi.". *International Journal for Parasitology*. **30** (4): 411–9. doi:10.1016/s0020-7519(00)00014-x. PMID 10731564.


Categories: Insect-borne diseases | Tropical diseases | Diseases of veins, lymphatic vessels and lymph nodes | Infectious diseases with eradication efforts